Efficacy of rivastigmine as a treatment for Alzheimer’s disease over five years

'The Alzheimer's Society is very pleased that researchers have looked at the long term effects of a rivastigmine, a cholinesterase inhibitor, in the treatment of Alzheimer's disease. There is not much evidence currently available to indicate the long term effects of these drugs.

However, we need studies that are longer than five years to determine long term effects. The Society hopes that long term studies will also take place for the other cholinesterase inhibitor drugs.

This research looks very promising and gives hope to people with dementia and their carers. It suggests that people with dementia can maintain their independence for longer if they have access to antidementia drugs.

People with Alzheimer's disease continue to be denied access to drugs that NICE approved as clinically- and cost-effective three years ago. These drugs are not a cure but they slow down the worsening of symptoms and improve quality of life for people with dementia and carers. People with Alzheimer's disease have a progressive, degenerative condition and cannot afford to wait for treatment.'

Dr Susanne Sorensen
Head of Research